SLRX
Salarius Pharmaceuticals Inc
-8.52%
$2.23 - $2.04
Feb 8th 2023 - Mar 22nd 2023
Jan, 20, 2023
$SLRX Enough cash flow for got damn 7!
Jan, 20, 2023
$HTGM primed for $10+: STRONG BUY signal 700K flo... See more
HTGM
HTG Molecular Diagnostics Inc
-37.26%
$4.67 - $2.93
Feb 7th 2023 - Mar 21st 2023
Mar, 15, 2023
The have enough cash to last them for the next 1.5... See more
Feb, 8, 2023
Additional cash coming in Friday so that will be fun.
TGTX
TG Therapeutics Inc
-19.05%
$18.43 - $14.92
Feb 7th 2023 - Mar 21st 2023
Jan, 30, 2023
Translate the data on this (today's sec releas... See more
Jan, 4, 2023
Approved, best in class drug with a huge market an... See more
Jan, 20, 2023
$SLRX Enough cash flow for got damn 7!
Jan, 20, 2023
$HTGM primed for $10+: STRONG BUY signal 700K float 500%+ Cost to Borrow $3M MC w/ $14M in cash Recent analyst targets of $15.00+ Excellent technical setup Also watching: $WISA $SLRX $GNUS
Jan, 20, 2023
$SLRX I like all the excitement on this board, and the $7.38 cash per share
Jan, 19, 2023
News, cash, high volume, no more halts as it's AH's. ;) π₯
Jan, 18, 2023
cash share is 7 π
Mar, 15, 2023
The have enough cash to last them for the next 1.5 years, no exposure to dilution and have 6 drugs in the pipeline.
Feb, 8, 2023
Additional cash coming in Friday so that will be fun.
Feb, 3, 2023
They have cash!
Feb, 3, 2023
I won't miss $HTGM micro float trading under cash with many catalysts ππ
Feb, 3, 2023
$HTGM Nice cash on hand.
Jan, 25, 2023
$HTGM with excellent technical setup for $12.00+ by end of week. Life science company w/ leading HTG tech: - 690K float - 900K shares outstanding -$3M MC w/ near 5x cash on hand -Highest CTB (515%!)
Jan, 21, 2023
On the threshold list for a month, plenty of cash , .
Jan, 20, 2023
$HTGM primed for $10+: STRONG BUY signal 700K float 500%+ Cost to Borrow $3M MC w/ $14M in cash Recent analyst targets of $15.00+ Excellent technical setup Also watching: $WISA $SLRX $GNUS
Jan, 30, 2023
Translate the data on this (today's sec release) Seems VERY positive and with a cash run into 2024 on worst case basis.
Jan, 4, 2023
Approved, best in class drug with a huge market and a nice pile of cash, it checks every box.
Dec, 29, 2022
Amazing positive news from the TGTX 20221229 conference call, FDA approved, π¨π₯π¨ Ublituximab Briumvi: 1) No need for additional funds, no offering, no need for capital raise, because 220 million in cash reserves expected to last until mid 2024.
Dec, 29, 2022
$TGTX Plenty of cash on hand and commercialization up and coming.